#United Arab Emirates #UAE #WAT Medical #MOHAP

WAT Medical Achieves Manufacturing Registration in the UAE

WAT Medical, a prominent player in the medical technology sector, has recently achieved a significant regulatory milestone by securing a Manufacturing Site Registration Certificate from the UAE Ministry of Health and Prevention (MOHAP) in June 2026. This accomplishment is a critical step in the company’s strategy to expand its footprint in the global market and particularly focuses on the Middle East region.

Strengthening Global Regulatory Presence

The Manufacturing Site Registration underscores WAT Medical’s commitment to maintaining high standards in medical device manufacturing. With this certification, the company confirms that its facilities adhere to the stringent regulatory requirements necessary for the production of medical devices in the UAE. This certification adds to WAT Medical's already impressive portfolio of global approvals, which includes endorsements from the FDA, Health Canada, and the TGA, along with certifications like MDSAP and ISO 13485. Such endorsements not only highlight the company’s compliance with international standards but also ensure the delivery of high-quality medical technologies to users worldwide.

Accelerating Market Entry in the Middle East

Following the acquisition of its Manufacturing Site Registration, WAT Medical plans to tap into the rapidly evolving healthcare market of the UAE. The company will work closely with its officially appointed Authorized Representative in the UAE to expedite the registration process for its innovative neuromodulation devices, HeadaTerm and EmeTerm. Once these devices receive the necessary approvals, WAT Medical intends to initiate their distribution within the UAE and gradually expand into further Middle Eastern markets, thereby enhancing accessibility to non-invasive treatment methods that benefit patients.

Growing Demand for Non-Pharmacological Treatments

The Middle East is witnessing a surge in the healthcare sector, characterized by an increasing demand for non-pharmaceutical treatment options. The UAE’s robust regulatory framework and strategic location make it a prime entry point for medical technology companies aiming for regional expansion. WAT Medical recognizes the potential to introduce non-drug neuromodulation solutions designed to meet the evolving preferences and requirements of healthcare in the region.

Committed to Innovation and Collaboration

With over a decade of experience in developing wearable neuromodulation devices, WAT Medical has conducted numerous clinical studies to demonstrate the safety and efficacy of its innovations. The company is not just focused on addressing immediate market needs; it is actively engaged in scientific research partnerships with prestigious institutions in the United States and Canada, including collaborations with Ohio State University and Concordia University. As part of its Middle East expansion strategy, establishing new research collaborations in the region is also a priority, aiming at further advancements in neuromodulation therapies.

Participation in Global Retail Event

As part of its comprehensive global strategy, WAT Medical is set to participate in Amazon Prime Day 2026, marking a decade of participation in this significant retail event. This involvement indicates the company’s commitment to making its innovative solutions—specifically those that are drug-free and focus on neuromodulation—more accessible to consumers worldwide.

The journey WAT Medical is pursuing reflects its tireless efforts to improve the quality of life through technology. With increased international visibility and the achievement of essential regulatory approvals, the company is poised for substantial growth in the healthcare sector.

WAT Medical expresses its sincere appreciation to its global customer base for their unwavering support, affirming its dedication to enhancing lives through cutting-edge medical technology.